{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:53:20Z","timestamp":1781650400416,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The tumour microenvironment (TME) may play a pivotal role in the development, progression, and prognosis of HCC. We aimed to investigate the prognostic association of the TME in Danish liver-resected patients with HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included all patients liver-resected for HCC between January 2000 and December 2016 with available tumour tissue stored in the diagnostic biobank. Resected tumour tissues and corresponding normal liver tissues were investigated for immune cell densities with immunohistochemistry. We investigated the association between individual immune cell densities and prognosis. We identified distinct patient groups based on hierarchical clustering and heatmap visualisation, for their association with prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 75 patients, 72% were male and median age was 66 years (58-72). Most patients had a single tumour, median size was 50 mm, and 57% without vascular invasion. Median follow-up was 44 months and 50% of the patients had a recurrence within the study period. The density of CD4+ T cells in the invasive margin was significantly associated with a higher risk of mortality (HR = 1.43, 95% CI: 1.13\u20131.82), whereas a higher density of tumour-associated macrophages in the tumour centre was significantly associated with a lower risk of cancer-related mortality (HR = 0.53, 95% CI: 0.28\u20131.00). Clustering of patients based on immune cell densities in tumour tissue revealed that those with lower immune cell counts exhibited significantly worse disease-free survival when compared to other patients (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TME had a prognostic association with survival, lending credence to spatial immune cell densities as important factors contributing to prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01467-1","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:16:26Z","timestamp":1776255386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival and Tumour Microenvironment in Spatially Distinct Regions in Patients Resected for Hepatocellular Carcinoma: A Multicentre Study"],"prefix":"10.1007","volume":"57","author":[{"given":"Sophie Bull","family":"Nordkild","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanett","family":"Klubien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delal","family":"Akdag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette Baehr","family":"Georgsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Switten","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Steiniche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda Elisabeth","family":"Villadsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Riegels","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro Linno","family":"Willemoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper B\u00f8je","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Dam","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christian Lykkegaard","family":"Pommergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"1467_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1467_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:1\u201328. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"1467_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/HEP.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4. https:\/\/doi.org\/10.1002\/HEP.31288.","journal-title":"Hepatology"},{"key":"1467_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/jhbp.745","volume":"28","author":"HC Pommergaard","year":"2021","unstructured":"Pommergaard HC, Preuss Hasselby J, Linno Willemoe G, Ralbovska A, Arendtsen Rostved A, Rasmussen A, et al. Peroxisome proliferator-activated receptor activity correlates with poor survival in patients resected for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2021;28:327\u201335. https:\/\/doi.org\/10.1002\/jhbp.745.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1467_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/S41575-019-0186-Y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589. https:\/\/doi.org\/10.1038\/S41575-019-0186-Y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1467_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA0804525","volume":"359","author":"Y Hoshida","year":"2008","unstructured":"Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995\u20132004. https:\/\/doi.org\/10.1056\/NEJMOA0804525.","journal-title":"N Engl J Med"},{"key":"1467_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.CCR.2006.06.016","volume":"10","author":"A Budhu","year":"2006","unstructured":"Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99\u2013111. https:\/\/doi.org\/10.1016\/J.CCR.2006.06.016.","journal-title":"Cancer Cell"},{"key":"1467_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/J.JHEP.2006.01.008","volume":"44","author":"SS Thorgeirsson","year":"2006","unstructured":"Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006;44:798\u2013805. https:\/\/doi.org\/10.1016\/J.JHEP.2006.01.008.","journal-title":"J Hepatol"},{"key":"1467_CR9","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","volume":"383","author":"EA Tsochatzis","year":"2014","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(14)60121-5.","journal-title":"Lancet"},{"key":"1467_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23073778","author":"Z Sas","year":"2022","unstructured":"Sas Z, Cendrowicz E, Weinh\u00e4user I, Rygiel TP. Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for new treatment options. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/IJMS23073778.","journal-title":"Int J Mol Sci"},{"key":"1467_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729705","author":"X Zheng","year":"2021","unstructured":"Zheng X, Jin W, Wang S, Ding H. Progression on the roles and mechanisms of tumor-infiltrating T lymphocytes in patients with hepatocellular carcinoma. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.729705.","journal-title":"Front Immunol"},{"key":"1467_CR12","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/IJC.24556","volume":"125","author":"J Zhou","year":"2009","unstructured":"Zhou J, Ding T, Pan W, Zhu L, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009;125:1640\u20138. https:\/\/doi.org\/10.1002\/IJC.24556.","journal-title":"Int J Cancer"},{"key":"1467_CR13","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/J.GASTRO.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology. 2016;150:1646-1658.e17. https:\/\/doi.org\/10.1053\/J.GASTRO.2016.02.040.","journal-title":"Gastroenterology"},{"key":"1467_CR14","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1158\/0008-5472.CAN-07-2354","volume":"67","author":"SK Bunt","year":"2007","unstructured":"Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67:10019\u201326. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2354.","journal-title":"Cancer Res"},{"key":"1467_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DAA Vignali","year":"2008","unstructured":"Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523\u201332. https:\/\/doi.org\/10.1038\/nri2343.","journal-title":"Nat Rev Immunol"},{"key":"1467_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/S40425-019-0814-7","volume":"7","author":"J Ma","year":"2019","unstructured":"Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, et al. PD1Hi CD8\u2009+\u2009T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7:331. https:\/\/doi.org\/10.1186\/S40425-019-0814-7.","journal-title":"J Immunother Cancer"},{"key":"1467_CR17","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.18632\/ONCOTARGET.27146","volume":"10","author":"C Tauber","year":"2019","unstructured":"Tauber C, Schultheiss M, De Luca R, Buettner N, Llewellyn-Lacey S, Emmerich F, et al. Inefficient induction of circulating TAA-specific CD8\u2009+\u2009T-cell responses in hepatocellular carcinoma. Oncotarget. 2019;10:5194\u2013206. https:\/\/doi.org\/10.18632\/ONCOTARGET.27146.","journal-title":"Oncotarget"},{"key":"1467_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/HEP.510270214","volume":"27","author":"Y Wada","year":"1998","unstructured":"Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27:407\u201314. https:\/\/doi.org\/10.1002\/HEP.510270214.","journal-title":"Hepatology"},{"key":"1467_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013301","author":"W Ding","year":"2018","unstructured":"Ding W, Xu X, Qian Y, Xue W, Wang Y, Du J, et al. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a meta-analysis. Medicine. 2018. https:\/\/doi.org\/10.1097\/MD.0000000000013301.","journal-title":"Medicine"},{"key":"1467_CR20","doi-asserted-by":"crossref","unstructured":"Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image Segmentation 2015.","DOI":"10.1007\/978-3-319-24574-4_28"},{"key":"1467_CR21","unstructured":"Kingma DP, Ba J, Adam. A Method for Stochastic Optimization 2014."},{"key":"1467_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/HEP.26054","volume":"58","author":"J Fu","year":"2013","unstructured":"Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J, et al. Impairment of CD4\u2009+\u2009cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology. 2013;58:139\u201349. https:\/\/doi.org\/10.1002\/HEP.26054.","journal-title":"Hepatology"},{"key":"1467_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0032493","author":"E Cariani","year":"2012","unstructured":"Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, Pelosi G, et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One. 2012. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0032493.","journal-title":"PLoS One"},{"key":"1467_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1746573","author":"F Liu","year":"2020","unstructured":"Liu F, Liu W, Sanin DE, Jia G, Tian M, Wang H, et al. Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. Oncoimmunology. 2020. https:\/\/doi.org\/10.1080\/2162402X.2020.1746573.","journal-title":"Oncoimmunology"},{"key":"1467_CR25","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","volume":"25","author":"Q Gao","year":"2007","unstructured":"Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586\u201393. https:\/\/doi.org\/10.1200\/JCO.2006.09.4565.","journal-title":"J Clin Oncol"},{"key":"1467_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013301","author":"W Ding","year":"2018","unstructured":"Ding W, Xu X, Qian Y, Xue W, Wang Y, Du J, et al. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma a meta-analysis. Medicine (United States). 2018. https:\/\/doi.org\/10.1097\/MD.0000000000013301.","journal-title":"Medicine (United States)"},{"key":"1467_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.7150\/JCA.51346","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Ge W, Zhou J, Gao B, Qian X, Wang W. The role of tumor associated macrophages in hepatocellular carcinoma. J Cancer. 2021;12:1284\u201394. https:\/\/doi.org\/10.7150\/JCA.51346.","journal-title":"J Cancer"},{"key":"1467_CR28","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/gut.2008.149062","volume":"57","author":"MA Silva","year":"2008","unstructured":"Silva MA, Hegab B, Hyde C, Guo B, Buckels JAC, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Hepatology. 2008;57:1592\u20136. https:\/\/doi.org\/10.1136\/gut.2008.149062.","journal-title":"Hepatology"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01467-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:06:39Z","timestamp":1781647599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01467-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01467-1","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Central Denmark Region Committees on Health Research Ethics (journal-nr.: 1-10-72-104-17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"During the preparation of this work, the authors used ChatGPT from OpenAI to improve clarity, grammar and readability of the manuscript. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations of Generative AI and AI-assisted Technologies in the Writing Process"}},{"value":"Informed consent has been obtained by all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"HC Pommergaard: Research grants from Danish Cancer Society, Svend Andersen Fund, Harboe Fund, Dagmar Marshalls Fund, and The Danish National Center for Circulating Tumor DNA Guided Cancer Treatment.SD Nielsen: Research grant from Novo Nordic Foundation and participation in advisory board for Gilead, Merck, and GSK.GE Villadsen: Vingmed A\/S, Sirtex EU, Astra-Zeneca DenmarkSB Nordkild, J Klubien, D Akdag, CJ O\u2019Rourke, JB Georgsen, PS Nielsen, T Steiniche, GE Villadsen, AR Knudsen, GL Willemoe, JB Andersen: Declarations of interest: none.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}